The Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Disease Severity in Hospitalized Patients with Community-Acquired Pneumonia
Keywords:
Community-acquired pneumonia, Neutrophil-to-lymphocyte ratio, CURB-65, Disease severity, PrognosisAbstract
Background: Community-acquired pneumonia (CAP) remains a major cause of hospitalization and mortality worldwide. Early identification of patients at risk of severe disease and poor outcomes is essential for appropriate triage and management. The neutrophil-to-lymphocyte ratio (NLR), derived from routine complete blood counts, has emerged as a potential prognostic biomarker in infectious diseases, including CAP. Objective: To evaluate the prognostic utility of the admission Neutrophil-to-Lymphocyte Ratio (NLR) for predicting disease severity and clinical outcomes in hospitalized patients with Community-Acquired Pneumonia (CAP). Methodology: This observational, prospective study was conducted at the Department of Medicine, Saidu Sharif Teaching Hospital, Swat, from January 2023 to April 2024. The research team enrolled a total of 150 adult patients through consecutive sampling who were hospitalized with community-acquired pneumonia radiologically confirmed by X-ray or CT-scan. Data on patients' demographics, clinical findings, laboratory parameters, and X-ray features were collected at admission. The severity of the disease was measured by the CURB-65 scoring system. The admission NLR was calculated by the absolute neutrophil and lymphocyte counts. Patients were followed up for outcomes like admission to the intensive care unit (ICU), requirement for mechanical ventilation, and in-hospital death. Results: The mean age of patients was 56.2 ± 15.7 years, with male predominance (57.3%). Severe CAP (CURB-65 ?3) was observed in 26.7% of patients. The mean NLR was significantly higher in patients with severe disease than in those with mild to moderate CAP (14.6 ± 6.1 vs. 7.9 ± 4.3; p < 0.001). Elevated NLR was strongly associated with ICU admission, mechanical ventilation, and mortality. A significant positive correlation was observed between NLR and CURB-65 score (r = 0.69, p < 0.001). Conclusion: An elevated admission NLR is a strong predictor of disease severity and adverse clinical outcomes in hospitalized patients with community-acquired pneumonia. NLR may serve as a useful adjunct to established severity scoring systems for early risk stratification.References
GBD 2019 LRI Collaborators. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022;22(11):1626-1647. DOI:10.1016/S1473-3099(22)00510-2.
Cillóniz C, Dominedò C, Torres A. An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. Curr Opin Infect Dis. 2019;32(6):656-665. DOI:10.1097/QCO.0000000000000596.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI:10.1164/rccm.201908-1581ST.
Ticona JH, Zaccone VM, McFarlane IM. Community-acquired pneumonia: A focused review. Am J Med Case Rep. 2021;9(1):45.
Siljan WW, Holter JC, Michelsen AE, Nymo SH, Lauritzen T, Oppen K, et al. Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study. ERJ open research. 2019;5(1). DOI:10.1183/23120541.00014-2019.
Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022;19(2):177-91. DOI:10.1038/s41423-021-00832-3.
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. Int J Mol Sci. 2022;23(7):3636. doi:10.3390/ijms23073636
Kumar P. Role of the Neutrophil-Lymphocyte Count Ratio in the Differential Diagnosis between Pulmonary Tuberculosis and Bacterial Community-Acquired Pneumonia. J Med Sci Clin Res. 2020;8(03):345-49. DOI:10.18535/jmscr/v8i3.60
Al Hussain SK, Kurdi A, Abutheraa N, AlDawsari A, Sneddon J, Godman B, et al. Validity of pneumonia severity assessment scores in Africa and South Asia: a systematic review and meta-analysis. InHealthcare 2021;9(9):1202. DOI:10.3390/healthcare9091202.
Demirdal T, Sen P. The significance of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and lymphocyte-monocyte ratio in predicting peripheral arterial disease, peripheral neuropathy, osteomyelitis and amputation in diabetic foot infection. Diabetes Res Clin Pract. 2018;144:118-125. DOI:10.1016/j.diabres.2018.08.009.
Lee JH, Song S, Yoon SY, Lim CS, Song WJ, Park KH. Neutrophil-to-lymphocyte ratio predicts short-term prognosis in patients with community-acquired pneumonia: a retrospective study. Eur J Clin Microbiol Infect Dis. 2020;39(9):1767-1774. DOI:10.1007/s10096-020-03897-6
Sharma BB, Singh S, Sharma VK, et al. Patterns, etiologies, and risk factors of environmentally related respiratory diseases in rural India: a study from Rajasthan. Lung India. 2018;35(6):502-508. DOI:10.4103/lungindia.lungindia_68_18.
Peyrani P, Arnold FW, Bordon J, Furmanek S, Luna CM, Cavallazzi R, et al. Incidence and mortality of adults hospitalized with community-acquired pneumonia according to clinical course. Chest. 2020;157(1):34-41. DOI:10.1016/j.chest.2019.09.022.
Aliberti S, Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia. Lancet. 2021;398(10303):906-19. DOI:10.1016/S0140-6736(21)00630-9.
Çilli A, Özdemir T, Özbudak Ö, Ö?ü? C, Kara A. Risk factors for the development of community-acquired pneumonia in young adults. Thoracic Research and Practice. 2021;2(01):3-7.
Olson G, Davis AM. Diagnosis and treatment of adults with community-acquired pneumonia. J Am Med Assoc. 2020;323(9):885-6. DOI:10.1001/jama.2019.21118.
Sakakibara T, Shindo Y, Kobayashi D, Sano M, Okumura J, Murakami Y, et al. A prediction rule for severe adverse events in all inpatients with community-acquired pneumonia: a multicenter observational study. BMC Pulm Med. 2022;22(1):34. DOI:10.1186/s12890-022-01819-0.
Feng DY, Zou XL, Zhou YQ, Wu WB, Yang HL, Zhang TT. Combined neutrophil-to-lymphocyte ratio and CURB-65 score in elderly CAP. Int J Gen Med. 2021;14:1133–1139. DOI:10.2147/IJGM.S300776
Alzoubi O, Khanfar A. Association between NLR and mortality in CAP: a meta-analysis. Monaldi Arch Chest Dis. 2021;92(1). DOI:10.4081/monaldi.2021.2050
Kuikel S, Pathak N, Poudel S, Thapa S, Bhattarai SL, Chaudhary G, NLR as a predictor of adverse outcomes in CAP. Health Sci Rep. 2022;5(4):e630. DOI:10.1002/hsr2.630.
Liu Q, Sun G, Huang L. Association of NLR with severity of CAP in older adults. Clin Lab. 2023;69(3). DOI:10.7754/Clin.Lab.2023.220330.
Lee H, Kim I, Kang BH, Um SJ. Prognostic value of serial neutrophil-to-lymphocyte ratio measurements in hospitalized community-acquired pneumonia. PLoS One. 2021;16(4):e0250067. DOI:10.1371/journal.pone.0250067.
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. 2022;23(7):3636. DOI:10.3390/ijms23073636.
Jiang J, Liu R, Yu X, Yang R, Xu H, Mao Z, et al. The neutrophil-lymphocyte count ratio as a diagnostic marker for bacteraemia: A systematic review and meta-analysis. Am J Emerg Med. 2019;37(8):1482-9. DOI:10.1016/j.ajem.2018.10.057.
Costa MI, Cipriano A, Santos FV, Valdoleiros SR, Furtado I, Machado A, et al. Clinical profile and microbiological aetiology diagnosis in adult patients hospitalized with community-acquired pneumonia. Pulmonology. 2022;28(5):358-67. DOI:10.1016/j.pulmoe.2020.11.003.
Zhang D, Yang D, Makam AN. Utility of blood cultures in pneumonia. Am J Med. 2019;132(10):1233–1238. DOI:10.1016/j.amjmed.2019.03.025.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Chest Medicine

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


